171 related articles for article (PubMed ID: 32843492)
1. IL-31 induces antitumor immunity in breast carcinoma.
Kan T; Feldman E; Timaner M; Raviv Z; Shen-Orr S; Aronheim A; Shaked Y
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32843492
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells.
Jovanovic IP; Pejnovic NN; Radosavljevic GD; Pantic JM; Milovanovic MZ; Arsenijevic NN; Lukic ML
Int J Cancer; 2014 Apr; 134(7):1669-82. PubMed ID: 24105680
[TBL] [Abstract][Full Text] [Related]
3. High IL-1R8 expression in breast tumors promotes tumor growth and contributes to impaired antitumor immunity.
Campesato LF; Silva APM; Cordeiro L; Correa BR; Navarro FCP; Zanin RF; Marçola M; Inoue LT; Duarte ML; Molgora M; Pasqualini F; Massara M; Galante P; Barroso-Sousa R; Polentarutti N; Riva F; Costa ET; Mantovani A; Garlanda C; Camargo AA
Oncotarget; 2017 Jul; 8(30):49470-49483. PubMed ID: 28533483
[TBL] [Abstract][Full Text] [Related]
4. Th9 cells promote antitumor immunity via IL-9 and IL-21 and demonstrate atypical cytokine expression in breast cancer.
You FP; Zhang J; Cui T; Zhu R; Lv CQ; Tang HT; Sun DW
Int Immunopharmacol; 2017 Nov; 52():163-167. PubMed ID: 28918288
[TBL] [Abstract][Full Text] [Related]
5. IL-15/IL-15Rα Heterodimeric Complex as Cancer Immunotherapy in Murine Breast Cancer Models.
Guo S; Smeltz RB; Nanajian A; Heller R
Front Immunol; 2020; 11():614667. PubMed ID: 33628206
[TBL] [Abstract][Full Text] [Related]
6. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
7. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
[TBL] [Abstract][Full Text] [Related]
8. L-Arginine supplementation inhibits the growth of breast cancer by enhancing innate and adaptive immune responses mediated by suppression of MDSCs in vivo.
Cao Y; Feng Y; Zhang Y; Zhu X; Jin F
BMC Cancer; 2016 Jun; 16():343. PubMed ID: 27246354
[TBL] [Abstract][Full Text] [Related]
9. Myeloid-derived suppressor cell depletion therapy targets IL-17A-expressing mammary carcinomas.
Dawod B; Liu J; Gebremeskel S; Yan C; Sappong A; Johnston B; Hoskin DW; Marshall JS; Wang J
Sci Rep; 2020 Aug; 10(1):13343. PubMed ID: 32770025
[TBL] [Abstract][Full Text] [Related]
10. Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response.
Cho HM; Rosenblatt JD; Tolba K; Shin SJ; Shin DS; Calfa C; Zhang Y; Shin SU
Cancer Res; 2010 Dec; 70(24):10121-30. PubMed ID: 21159634
[TBL] [Abstract][Full Text] [Related]
11. Recombinant virus-like particles presenting IL-33 successfully modify the tumor microenvironment and facilitate antitumor immunity in a model of breast cancer.
Feng X; Liu H; Chu X; Sun P; Huang W; Liu C; Yang X; Sun W; Bai H; Ma Y
Acta Biomater; 2019 Dec; 100():316-325. PubMed ID: 31542504
[TBL] [Abstract][Full Text] [Related]
12. Melanoma differentiation-associated gene-7 (mda-7)/interleukin (IL)-24 induces anticancer immunity in a syngeneic murine model.
Miyahara R; Banerjee S; Kawano K; Efferson C; Tsuda N; Miyahara Y; Ioannides CG; Chada S; Ramesh R
Cancer Gene Ther; 2006 Aug; 13(8):753-61. PubMed ID: 16543916
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma.
Nakano H; Kishida T; Asada H; Shin-Ya M; Shinomiya T; Imanishi J; Shimada T; Nakai S; Takeuchi M; Hisa Y; Mazda O
J Gene Med; 2006 Jan; 8(1):90-9. PubMed ID: 16097036
[TBL] [Abstract][Full Text] [Related]
14. Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer.
Ma YF; Chen C; Li D; Liu M; Lv ZW; Ji Y; Xu J
Oncotarget; 2017 Jan; 8(5):7614-7624. PubMed ID: 27935862
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.
Søndergaard H; Galsgaard ED; Bartholomaeussen M; Straten PT; Odum N; Skak K
J Immunother; 2010 Apr; 33(3):236-49. PubMed ID: 20445344
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-7 enhances the in vivo anti-tumor activity of tumor-reactive CD8+ T cells with induction of IFN-gamma in a murine breast cancer model.
Yuan CH; Yang XQ; Zhu CL; Liu SP; Wang BC; Wang FB
Asian Pac J Cancer Prev; 2014; 15(1):265-71. PubMed ID: 24528037
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer.
Hartl CA; Bertschi A; Puerto RB; Andresen C; Cheney EM; Mittendorf EA; Guerriero JL; Goldberg MS
J Immunother Cancer; 2019 Jul; 7(1):199. PubMed ID: 31362778
[TBL] [Abstract][Full Text] [Related]
18. TFEB is a master regulator of tumor-associated macrophages in breast cancer.
Li Y; Hodge J; Liu Q; Wang J; Wang Y; Evans TD; Altomare D; Yao Y; Murphy EA; Razani B; Fan D
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32487570
[TBL] [Abstract][Full Text] [Related]
19. Potent antitumor activity of interleukin-27.
Hisada M; Kamiya S; Fujita K; Belladonna ML; Aoki T; Koyanagi Y; Mizuguchi J; Yoshimoto T
Cancer Res; 2004 Feb; 64(3):1152-6. PubMed ID: 14871851
[TBL] [Abstract][Full Text] [Related]
20. Lentinan Inhibits Tumor Progression by Immunomodulation in a Mouse Model of Bladder Cancer.
Sun M; Bu R; Zhang B; Cao Y; Liu C; Zhao W
Integr Cancer Ther; 2020; 19():1534735420946823. PubMed ID: 32735179
[No Abstract] [Full Text] [Related]
[Next] [New Search]
